Perspectives in antisense therapeutics

Pharmacology and Therapeutics

Volumn 76, Issue 1-3, 1997, Pages 151-160

  Agrawal, Sudhir ^a   Iyer, Radhakrishnan P ^a  

^a HYBRIDON INC   (United States)

Author keywords

Mixed backbone oligonucleotides; Oligonucleoside phosphorothioates; Oral bioavailability; Pharmacokinetics; Toxicology

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; BASE PAIRING; BINDING AFFINITY; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG STABILITY; DRUG TARGETING; GENE EXPRESSION REGULATION; HYDROGEN BOND; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECONDARY STRUCTURE; RAT; REVIEW; STRUCTURE ANALYSIS; TISSUE DISTRIBUTION;

ANIMALS; DNA; DRUG DESIGN; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0031278019     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(97)00108-3     Document Type: Review

References (35)

1. Agrawal, S. (ed.) (1996a) Antisense Therapeutics. Humana Press, Totowa.
2. Agrawal, S. (1996b) Antisense oligonucleotides: towards clinical trials. Trends Biotechnol. 14: 376-387.
3. Agrawal, S. and Iyer, R. P. (1995) Modified oligonucleotides as therapeutic and diagnostic agents. Curr. Opin. Biotechnol. 6: 12-19.
4. Agrawal, S., Temsamani, J. and Tang, J.-Y. (1991) Pharmacokinetics, biodistribution and stability of oligodeoxynucleoside phosphorothioates in mice. Proc. Natl. Acad. Sci. USA 88: 7595-7599.
5. Agrawal, S., Temsamani, J., Galbraith, W. and Tang, J.-Y. (1995a) Pharmacokinetics of antisense oligonucleotides. Clin. Pharmacokinet. 28: 7-16.
6. Agrawal, S., Zhang, X., Lu, Z., Hui, Z., Tamburin, M. J., Yan, J., Cai, H., Diasio, R. B., Habus, I., Iyer, R. P., Yu, D. and Zhang, R. (1995b) Absorption, tissue distribution, and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. Biochem. Pharmacol. 50: 571-576.
7. Agrawal, S., Rustagi, P. K. and Shaw, D. (1996) Novel enzymatic and immunological responses to oligonucleotides. Toxicol. Lett. 82/83: 431-434.
8. Agrawal, S., Jiang, Z., Zhao, Q., Shaw, D., Cai, Q., Roskey, A., Channavajjala, L., Saxinger, C. and Zhang, R. (1997) Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies. Proc. Natl. Acad. Sci. USA 94: 2620-2625.
9. Cornish, K. G., Iverson, P., Smith, L., Arneson, M. and Bayever, E (1993) Cardiovascular effects of a phosphorothioate oligonucleotide with sequence antisense to p53 in the conscious rhesus monkey. Pharmacol. Commun. 3: 239-247.
10. 14C-labeled phosphorothioate oligonucleotide ISIS 2105, after intravenous administration to rats. J. Pharmacol. Exp. Ther. 267: 1181-1190.
11. 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intradermal administration to rats. J. Pharmacol. Exp. Ther. 269: 89-94.
12. Crooke, S. T. and Lebleu, R. (eds.) (1993) Antisense Research and Applications. CRC Press, Boca Raton.
13. Galbraith, W. M., Hobson, W. C., Giclas, P. C., Schechter, P. J. and Agrawal, S. (1994) Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res. Dev. 4: 201-206.
14. Giles, R. V., Spiller, D. G. and Tidd, D. M. (1995) Detection of ribonuclease H-generated mRNA fragments in human leukemia cells following reversible membrane permeabilization in the presence of antisense oligodeoxynucleotides. Antisense Res. Dev. 5: 23-31.
15. Helene, C. and Toulme, J. (1992) Specific regulation of gene expression by antisense, sense, and antigene nucleic acids. Biochim. Biophys. Acta 1049: 99-125.
16. Iverson, P. L. (1993) In vivo studies with phosphorothioate oligonucleotide: rationale for systemic therapy. In: Antisense Research and Applications, pp. 461-469, Crooke, S. T. and Lebleu, B. (eds.) CRC Press, Boca Raton.
17. Iverson, P. L., Copple, B. L., Tewary, H. K., Bayever, E. and Bishop, M. R. (1996) Continuous infusion of antisense phosphorothioate therapeutics. In: Antisense Therapeutics, pp. 201-212, Agrawal, S. (ed.) Human Press, Totowa.
18. Leeds, J. M., Kornbrust, D., Truong, L. and Henry, S. (1994) Metabolism and pharmacokinetic analysis of a phosphorothioate oligonucleotide after intravitreal injection. Pharm. Res. 11: S-353.
19. Metelev, V., Lisziewicz, J. and Agrawal S. (1994) Study of antisense oligonucleotide phosphorothioates containing segments of oligodeoxynucleotides and 2′-O-methyloligoribonucleotides. Bioorg. Med. Chem. Lett. 4: 2929-2934.
20. Miller, P. S., Ts'O, P. O. P., Hogrefe, R. I., Reynolds, M. A. and Arnold, I. J. (1993) Anticode oligonucleoside tnethylphosphonates and their psoralen derivatives. In: Antisense Research and Applications, pp. 189-203, Crooke, S. T. and Lebleu, B. (eds.) CRC Press, Boca Raton.
21. +/Pi cotransporter by antisense oligonucleotides. Proc. Natl. Acad. Sci. USA 93: 4903-4906.
22. Rappaport, J., Hanss, B., Kopp, J. B., Copeland, T. D., Bruggeman, L. A., Coffman, T. M. and Klotman, P. E. (1995) Transport of phosphorothioate oligonucleotides in kidney: implications for molecular therapy. Kidney Int. 47: 1462-1469.
23. 3H-labeled oligonucleotides: comparison of a phosphodiester and a phosphorothioate. Mol. Pharmacol. 45: 932-943.
24. Sarin, P. S., Agrawal, S., Civiera, M. P., Goodchild, J., Ikeuchi, T. and Zamecnik, P. C. (1988) Inhibition of acquired immunodeficiency syndrome virus by oligonucleoside methylphosphonates. Proc. Natl. Acad. Sci. USA 85: 7448-7451.
25. Sarmiento, U. M., Perez, J. R., Becker, J. M. and Narayanan, R. (1994) In vivo toxicological effects of rel A antisense phosphorothioates in CD-1 mice. Antisense Res. Dev. 4: 99-107.
26. Sawai, K., Miyao, T., Takakura, Y. and Hashida, M. (1995) Renal disposition characteristics of oligonucleotides modified at terminal linkages in the perfused rat kidney. Antisense Res. Dev. 5: 279-287.
27. Srinivasan, S. K. and Iverson, L. (1995) Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides. J. Clin. Lab. Anal. 9: 129-137.
28. Verspieren, P., Loreau, N. L., Thuong, N. T., Shire, D. and Toulme, J. J. (1990) Effect of RNA secondary structure and modified bases on the inhibition of trypanosomid protein synthesis in cell free extracts by antisense oligodeoxynucleotides. Nucl. Acids Res. 18: 4711-4717.
29. Wickstrom, E. (ed.) (1991) Prospects for Antisense Nucleic Acid Therapy of Cancer and AIDS. Wiley-Liss, New York.
30. Zamecnik, P. C. (1996) History of antisense oligonucleotides, In: Antisense Therapeutics, pp. 1-11, Agrawal, S. (ed.) Humana Press, Totowa.
31. Zamecnik, P. C. and Stephenson, M. L. (1978) Inhibition of Rous sarcoma virus replication and transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA 75: 280-284.
32. Zhang, R., Diasio, R. B., Lu, Z., Liu, T., Jiang, Z., Galbraith, W. and Agrawal, S. (1995a) Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleoside phosphorothioate (GEM 91®) developed as a therapeutic agent for human immunodeficiency virus type-1. Biochem. Pharmacol. 49: 929-939.
33. Zhang, R., Lu, Z., Zhang, H., Diasio, R. B., Habus, I., Jiang, Z., Iyer, R. P., Yu, D. and Agniwal, S. (1995b) In vivo stability and metabolism of a "hybrid" oligonucleotide phosphorothioate in rats. Biochem. Pharmacol. 50: 545-556.
34. Zhang, R., Yan, J., Shahinian, H., Amm, G., Lu, Z., Liu, T., Saag, M. S., Jiang, Z., Temsamani, J., Martin, R. R., Schechter, P., Agrawal, S. and Diasio, R. B. (1995c) Pharmacokinetics of an oligodeoxynucleotide phosphorothioate (GEM 91®) in HIV-infected subjects. Clin. Pharmacol. Ther. 58: 44-53.
35. Zhang, R., Iyer, R. P., Yu, D., Tan, W., Zhang, X., Lu, Z., Zhao, H. and Agrawal, S. (1996) Pharmacokinetics and tissue disposition of a chimeric oligodeoxynucleotide phosphorothioate in rats after intravenous administration. J. Pharmacol. Exp. Ther. 278: 971-979.